How Do I Identify Patients at Risk for a Secondary Event Following an Initial Acute Ischemic Stroke?

August 3, 2021
Identification of patients at high risk for secondary ischemic event, after initial event or post TIA...is minimal tissue damage really that big of a deal related to secondary stroke? Drs. Galen Henderson of Brigham and Women’s Hospital and Jordan Bonomo of the University of Cincinnati discuss key perspectives from a neurocritical, emergency medicine, and stroke perspective related to this important area of medicine.
0 Comments

What Is the Clinical Impact of the Genetic Polymorphism Observed with the Effectiveness of some P2Y12 Inhibitors?

August 3, 2021
The association of genetic polymorphisms and P2Y12 inhibitors in regards to efficacy for patients with ischemic stroke or transient ischemic attack (TIA) remains controversial. Drs. Deepak Bhatt of Brigham and Women’s Hospital and Natalie Kreitzer of the University of Cincinnati discuss key perspectives from a neurocritical, emergency medicine, and stroke perspective related to this important area of medicine.
0 Comments

“Gaming the Conversation”: What Really Happens in Your Mind When You Are Evaluating a Patient for Acute Stroke Diagnosis and Treatment?

May 25, 2021
Learn what really happens in the mind of a stroke expert during the evaluation of an acute stroke patient. How to avoid pitfalls and how to make sure the patients you are caring for understand what is happening. Dr. Knight guides listeners through the steps to effectively diagnose and treat acute stroke patients.
0 Comments

Challenges in Endovascular Therapy for Acute Stroke- What Should the Rest of Us Know?

May 11, 2021
Endovascular treatment of acute stroke is intimidating to many providers. Dr. Grossman takes this opportunity to share his expertise and help the rest of us understand what neurointervention can do for acute stroke patients and what the future of endovascular stroke care holds.
0 Comments

What Was Missing From the NINDS Trial?

December 4, 2020
The NINDS trial was the seminal study of IV-tPA in the treatment of acute stroke. Yet controversy still exists around the trial methodology and the interpretation of the data. Was anything missing from NINDS? Does it still resonate nearly 25 years later?
0 Comments
RSS
123
Categories
More Entries